Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 4.70B | 5.43B | 6.28B | 6.52B | 13.98B |
| Total Depreciation and Amortization | 3.91B | 3.45B | 3.16B | 3.12B | 3.13B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 800.00M | 783.00M | 757.00M | 729.00M | 1.14B |
| Change in Net Operating Assets | -557.00M | 251.00M | -732.00M | -803.00M | -9.13B |
| Cash from Operations | 8.86B | 9.91B | 9.46B | 9.57B | 9.12B |
| Capital Expenditure | -2.10B | -2.08B | -2.09B | -2.17B | -2.20B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -20.10B | -20.04B | -19.90B | -105.00M | -85.00M |
| Divestitures | -- | -- | -- | -- | 0.00 |
| Other Investing Activities | -94.00M | -249.00M | -287.00M | -146.00M | -88.00M |
| Cash from Investing | -22.30B | -22.37B | -22.28B | -2.42B | -2.38B |
| Total Debt Issued | 19.86B | 19.92B | 19.90B | 5.00M | 4.00M |
| Total Debt Repaid | -4.23B | -3.39B | -2.00B | -1.62B | -2.16B |
| Issuance of Common Stock | 224.00M | 193.00M | 225.00M | 396.00M | 416.00M |
| Repurchase of Common Stock | -1.54B | -1.83B | -793.00M | -893.00M | -906.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.32B | -4.26B | -4.19B | -4.12B | -4.04B |
| Other Financing Activities | 0.00 | 0.00 | -82.00M | -82.00M | -82.00M |
| Cash from Financing | 9.99B | 10.64B | 13.06B | -6.31B | -6.77B |
| Foreign Exchange rate Adjustments | -12.00M | -23.00M | 24.00M | 71.00M | -18.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.46B | -1.85B | 271.00M | 906.00M | -47.00M |